G蛋白偶联受体（GPCR）标靶化：技术与全球市场

全球 G 蛋白偶联受体 (GPCR)标靶化市场规模预计将从 2024 年的 44 亿美元增长到 2029 年底的 61 亿美元，预测期内的复合年增长率为 6.8%。

预计北美市场将从 2024 年的 18 亿美元成长到 2029 年底的 23 亿美元，预测期内的复合年增长率为 5.8%。预计欧洲市场将从 2024 年的 12 亿美元成长到 2029 年底的 18 亿美元，预测期内的复合年增长率为 7.1%。

本报告涵盖全球 G 蛋白偶联受体 (GPCR)标靶化市场，并提供市场概述、市场影响因素和市场机会分析、法律制度、新兴技术和技术发展趋势、市场规模趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

目录

第一章执行摘要

• 市场展望
• 研究范围
• 市场摘要

第二章 市场概述

• 概述
• GPCR的类型
• GPCR 的细胞反应：简介
• GPCR在疾病生理学中的重要性
• 监管方面

第三章 市场动态

• 概述
• 市场驱动因素
• 慢性病发生率上升
• GPCR药物需求不断增加
• GPCR研究的技术进展
• 市场限制
• 药物研发挑战
• GPCR结构研究的局限性
• 市场机会
• 个人化癌症治疗

第四章 新兴科技与发展

• 概述
• 新兴技术
• 新的筛检技术
• GPCR标靶药物研发中的结构分析
• GPCR标靶药物研发的实验筛检
• 专利分析
• 专利审查：按申请人

第五章市场区隔分析

• 市场概览
• 细分市场
• GPCR标靶化：技术与全球市场
• 按检测类型进行的市场分析
• cAMP 和 cGMP 检测
• 钙功能测定
• Arrestin功能测定
• 放射性配体结合和 GTPγS 功能分析
• 报导基因分析
• 其他的
• 按产品类型进行市场分析
• 细胞株
• 检测试剂套件
• 细胞培养试剂
• 配体
• 市场分析：按应用
• 肿瘤/癌症
• 心血管疾病
• 中枢神经系统疾病
• 呼吸系统疾病
• 其他的
• 地理分布
• 市场分析：按地区
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第六章 竞争讯息

• 概述
• 产业公司排名
• 产业创业融资

第七章 GPCR 目标科技产业的永续性：ESG 视角

• 全球GPCR产业的永续性
• ESG风险与评级等：解读数据
• BCC 的观点

第 8 章 附录

• 来源
• 简称
• 公司简介
• AGILENT TECHNOLOGIES INC.
• BD
• DANAHER CORP.
• ENZO BIOCHEM INC.
• EPICS THERAPEUTICS
• EUROFINS SCIENTIFIC
• INTERAX BIOTECH AG
• MERCK KGAA
• ORION BIOTECHNOLOGY CANADA LTD.
• PROMEGA CORP.
• QIAGEN
• REVVITY
• TECTONIC THERAPEUTIC
• THERMO FISHER SCIENTIFIC INC.
• WUXI APPTEC

The global G protein-coupled receptor (GPCR) market is expected to grow from $4.4 billion in 2024 and is projected to reach $6.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029.

The North American GPCR market is expected to grow from $1.8 billion in 2024 and is projected to reach $2.3 billion by the end of 2029, at a CAGR of 5.8% during the forecast period of 2024 to 2029.

The European GPCR market is expected to grow from $1.2 billion in 2024 and is projected to reach $1.8 billion by the end of 2029, at a CAGR of 7.1% during the forecast period of 2024 to 2029.

Report Scope:

This report on the global market for G protein-coupled receptor (GPCR) targeting technologies analyzes the current landscape, including market size and growth trends and segments the market by assay type, product type, application and region. Assay categories include cAMP assays and cGMP assays, calcium functional assays, arrestin functional assays, radioligand binding and GTPgammaS functional assays, reporter gene assays and others. Product types include cell lines, detection kits, cell culture reagents and ligands. Applications include oncology, cardiovascular diseases (CVDs), central nervous system diseases, respiratory diseases and others.

The regions looked at are North America (the U.S., Canada and Mexico), Europe (Germany, the U.K., France, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore and Rest of APAC) and the Rest of the World (South America, the Middle East and Africa). The report also includes profiles of leading companies and discusses industry trends, significant products, mergers and acquisitions, and other collaborations or partnerships.

In-text citations are given by the author and the year that the research or study was published. More details on these sources can be found in the table listing them in the Appendix.

Report Includes:

• 22 data tables and 43 additional tables
• An analysis of the global market and technologies for G-protein coupled receptor (GPCR) targeting
• Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Evaluation of the market potential for GPCR targeting technology, industry growth drivers, and forecasts for this market's segments and sub-segments
• Estimates of the market size and revenue forecast for the global GPCR targeting technology market in USD millions, and a corresponding market share analysis by assay type, product type, application and region
• Discussion of the major market dynamics and shifts, and the regulations, industry challenges and macroeconomic factors affecting the demand for GPCR targeting technology over the coming years
• A look at the recent technological breakthroughs in the use of GPCR targeting technology, and how it has propelled the rapid growth in genetic engineering and advanced pharmacological research
• Review of the patent filings and research publications for innovations in GPCR targeting technology
• Discussion on the industry's ESG challenges and practices
• Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances or other advantages
• Insights into the industry structure for GPCR targeting technology, the competitive landscape, clinical trials and ongoing research activity
• Profiles of the major players in the industry, including Promega Corp., Revvity Inc., Thermo Fisher Scientific Inc., Enzo Biochem Inc., and Danaher Corp.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Types of GPCRs
• Introduction of GPCR Cellular Responses
• Importance of GPCRs in Disease Physiology
• Regulatory Aspect

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Rising Incidence of Chronic Diseases
• Growing Demand for GPCR Drugs
• Technological Advances in GPCR Research
• Market Restraints
• Challenges of Drug Discovery
• Limitations of GPCR Structural Studies
• Market Opportunities
• Personalized Cancer Therapy

Chapter 4 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• Novel Screening Technology
• Structural Analysis in GPCR-Targeted Drug Discovery
• Experimental Screening in GPCR-Targeted Drug Discovery
• Patent Analysis
• Patent Review, by Applicant

Chapter 5 Market Segmentation Analysis

• Market Overview
• Segmentation Breakdown
• GPCR-Targeting: Technologies and Global Markets
• Market Analysis by Assay Type
• cAMP Assays and cGMP Assays
• Calcium Functional Assays
• Arrestin Functional Assays
• Radioligand-Binding and GTPgammaS Functional Assays
• Reporter Gene Assays
• Other Assays
• Market Analysis by Product Type
• Cell Lines
• Detection Kits
• Cell Culture Reagents
• Ligands
• Market Analysis by Application
• Oncology/Cancers
• Cardiovascular Diseases
• Central Nervous System Diseases
• Respiratory Diseases
• Other Diseases
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 Competitive Intelligence

• Overview
• Ranking of Companies in the Industry
• Venture Fundings in the Industry

Chapter 7 Sustainability in the GPCR-Targeting Technologies Industry: An ESG Perspective

• Sustainability in the Global GPCR Industry
• ESG Risks and Ratings: Understanding the Data
• BCC Research Viewpoint

Chapter 8 Appendix

• Sources
• Abbreviations
• Company Profiles
• AGILENT TECHNOLOGIES INC.
• BD
• DANAHER CORP.
• ENZO BIOCHEM INC.
• EPICS THERAPEUTICS
• EUROFINS SCIENTIFIC
• INTERAX BIOTECH AG
• MERCK KGAA
• ORION BIOTECHNOLOGY CANADA LTD.
• PROMEGA CORP.
• QIAGEN
• REVVITY
• TECTONIC THERAPEUTIC
• THERMO FISHER SCIENTIFIC INC.
• WUXI APPTEC

List of Tables

• Summary Table : Global Market for GPCR-Targeting Technologies, by Region, Through 2029
• Table 1 : Number of New Cases and Deaths Due to Various Cancers, Globally, 2022
• Table 2 : U.S. NIH Funding for Various Diseases and Conditions, 2019-2023
• Table 3 : FDA-Approved Drugs Targeting GPCR, 2020-2024
• Table 4 : Patents Issued for GPCRs, by Applicant, January 2023-December 2024
• Table 5 : Global Market for GPCR-Targeting Technologies, Through 2029
• Table 6 : Global Market for GPCR Targeting Technologies, by Assay Type, Through 2029
• Table 7 : Global Market for GPCR-Targeting Technologies, by Product Type, Through 2029
• Table 8 : Global Market for GPCR-Targeting Technologies, by Application, Through 2029
• Table 9 : GPCRs, Ligands and Their Locations in the Body
• Table 10 : GPCR Families and Their Role in CNS Disorders
• Table 11 : Glucocorticoid Effects Mediated by Transactivation Mechanisms in Airway Structural Cells
• Table 12 : Global Market for GPCR-Targeting Technologies, by Region, Through 2029
• Table 13 : North American Market for GPCR-Targeting Technologies, by Country, Through 2029
• Table 14 : European Market for GPCR-Targeting Technologies, by Country, Through 2029
• Table 15 : APAC Market for GPCR-Targeting Technologies, by Country, Through 2029
• Table 16 : ROW Market for GPCR-Targeting Technologies, by Subregion, Through 2029
• Table 17 : Market Rankings of Leading Companies in the GPCR-Targeting Technologies Industry, 2023
• Table 18 : Funding for GPCR-Targeting Technologies Companies, 2022-2024
• Table 19 : ESG Rankings for Major GPCR Companies, 2024*
• Table 20 : Sources Used in this Report
• Table 21 : Abbreviations Used in this Report
• Table 22 : Agilent Technologies Inc.: Company Snapshot
• Table 23 : Agilent Technologies Inc.: Financial Performance, FY 2022 and 2023
• Table 24 : Agilent Technologies Inc.: Product Portfolio
• Table 25 : BD: Company Snapshot
• Table 26 : BD: Financial Performance, FY 2023 and 2024
• Table 27 : BD: Product Portfolio
• Table 28 : Danaher Corp.: Company Snapshot
• Table 29 : Danaher Corp.: Financial Performance, FY 2022 and 2023
• Table 30 : Danaher Corp.: Product Portfolio
• Table 31 : Enzo Biochem Inc.: Company Snapshot
• Table 32 : Enzo Biochem Inc.: Financial Performance, FY 2023 and 2024
• Table 33 : Enzo Biochem Inc.: Product Portfolio
• Table 34 : Epics Therapeutics: Company Snapshot
• Table 35 : Epics Therapeutics: Product Portfolio
• Table 36 : Eurofins Scientific: Company Snapshot
• Table 37 : Eurofins Scientific: Financial Performance, FY 2022 and 2023
• Table 38 : Eurofins Scientific: Product Portfolio
• Table 39 : InterAx Biotech AG: Company Snapshot
• Table 40 : InterAx Biotech AG: Product Portfolio
• Table 41 : Merck KGaA: Company Snapshot
• Table 42 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 43 : Merck KGaA: Product Portfolio
• Table 44 : Orion Biotechnology Canada Ltd.: Company Snapshot
• Table 45 : Orion Biotechnology Canada Ltd.: Product Portfolio
• Table 46 : Promega Corp.: Company Snapshot
• Table 47 : Promega Corp.: Product Portfolio
• Table 48 : Promega Corp.: News/Key Developments, 2023 and 2024
• Table 49 : Qiagen: Company Snapshot
• Table 50 : Qiagen: Financial Performance, FY 2022 and 2023
• Table 51 : Qiagen: Product Portfolio
• Table 52 : Revvity: Company Snapshot
• Table 53 : Revvity: Financial Performance, FY 2022 and 2023
• Table 54 : Revvity: Product Portfolio
• Table 55 : Revvity: News/Key Developments, 2021
• Table 56 : Tectonic Therapeutic: Company Snapshot
• Table 57 : Tectonic Therapeutic: Product Portfolio
• Table 58 : Tectonic Therapeutic: News/Key Developments, 2024
• Table 59 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 60 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
• Table 61 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 62 : Wuxi AppTec: Company Snapshot
• Table 63 : Wuxi AppTec: Financial Performance, FY 2022 and 2023
• Table 64 : Wuxi AppTec: Product Portfolio

List of Figures

• Summary Figure : Global Market Shares for GPCR-Targeting Technologies, by Region, 2023
• Figure 1 : Snapshot of the Market Dynamics for GPCR-Targeting Technologies
• Figure 2 : Global Market Shares for GPCR-Targeting Technologies, by Assay Type, 2023
• Figure 3 : Global Market Shares for GPCR-Targeting Technologies, by Product Type, 2023
• Figure 4 : Global Market Shares for GPCR-Targeting Technologies, by Application, 2023
• Figure 5 : Global Market Shares for GPCR-Targeting Technologies, by Region, 2023
• Figure 6 : North American Market Shares for GPCR-Targeting Technologies, by Country, 2023
• Figure 7 : European Market Shares for GPCR-Targeting Technologies, by Country, 2023
• Figure 8 : APAC Market Shares for GPCR-Targeting Technologies, by Country, 2023
• Figure 9 : ROW Market Shares for GPCR-Targeting Technologies, by Subregion, 2023
• Figure 10 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 11 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 12 : BD: Revenue Share, by Business Unit, FY 2024
• Figure 13 : BD: Revenue Share, by Country/Region, FY 2024
• Figure 14 : Danaher Corp.: Revenue Share, by Business Unit, FY 2023
• Figure 15 : Danaher Corp.: Revenue Share, by Country/Region, FY 2023
• Figure 16 : Enzo Biochem Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 17 : Eurofins Scientific: Revenue Share, by Business Unit, FY 2023
• Figure 18 : Eurofins Scientific: Revenue Share, by Country/Region, FY 2023
• Figure 19 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
• Figure 20 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
• Figure 21 : Qiagen: Revenue Share, by Business Unit, FY 2023
• Figure 22 : Qiagen: Revenue Share, by Country/Region, FY 2023
• Figure 23 : Revvity: Revenue Share, by Business Unit, FY 2023
• Figure 24 : Revvity: Revenue Share, by Country/Region, FY 2023
• Figure 25 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
• Figure 26 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023
• Figure 27 : Wuxi AppTec: Revenue Share, by Business Unit, 2023
• Figure 28 : Wuxi AppTec: Revenue Share, by Country/Region, 2023